Cargando…

Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France

AIMS: This analysis aims to evaluate the budget impact of intravenous iron therapy with ferric carboxymaltose for patients with systolic chronic heart failure and iron deficiency, from the perspective of the French public health insurance. METHODS AND RESULTS: A budget impact model was adapted to fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourguignon, Sandrine, Faller, Mathilde, Champs, François‐Olivier, Moutier, Hélène, Levesque, Karine, Caranhac, Gilbert, Cohen‐Solal, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487717/
https://www.ncbi.nlm.nih.gov/pubmed/31021531
http://dx.doi.org/10.1002/ehf2.12432
_version_ 1783414541236830208
author Bourguignon, Sandrine
Faller, Mathilde
Champs, François‐Olivier
Moutier, Hélène
Levesque, Karine
Caranhac, Gilbert
Cohen‐Solal, Alain
author_facet Bourguignon, Sandrine
Faller, Mathilde
Champs, François‐Olivier
Moutier, Hélène
Levesque, Karine
Caranhac, Gilbert
Cohen‐Solal, Alain
author_sort Bourguignon, Sandrine
collection PubMed
description AIMS: This analysis aims to evaluate the budget impact of intravenous iron therapy with ferric carboxymaltose for patients with systolic chronic heart failure and iron deficiency, from the perspective of the French public health insurance. METHODS AND RESULTS: A budget impact model was adapted to forecast the budget impact over 5 years, according to two scenarios: one where patients receive ferric carboxymaltose according to market share forecast and another where patients are not treated for iron deficiency. Clinical data were extrapolated from pooled data from four randomized controlled trials. The time horizon was extended to 5 years by applying transition probabilities estimated from the CONFIRM‐HF trial. Epidemiological parameters for France were derived from the literature. Cost parameters were derived from national available databases. In the base case analysis, the modelled 5 year cost difference between the scenarios with ferric carboxymaltose vs. no iron deficiency treatment in a population of 189 334 prevalent and incident patients led to €0.8m savings. The cumulative savings resulted from a reduction in the hospitalization costs associated with worsening heart failure (€−35.8m) as well as a reduction in the follow‐up costs (€−2.9m). These cost savings outweighed the costs of ferric carboxymaltose treatment (€37.7m). Sensitivity analyses showed that the budget impact varied from €−34m to €+146m. Parameters with the most impact on the budget were the hospitalization rate for patients not treated for iron deficiency, the number of ambulatory sessions needed, the absence of hospitalization cost differentiation between New York Heart Association classes, and administration settings costs. CONCLUSIONS: Iron deficiency treatment with ferric carboxymaltose in systolic chronic heart failure patients results in an improvement of New York Heart Association class and thereby increases the well‐being of the patients, while providing an overall cost saving for the French national health insurance.
format Online
Article
Text
id pubmed-6487717
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64877172019-05-06 Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France Bourguignon, Sandrine Faller, Mathilde Champs, François‐Olivier Moutier, Hélène Levesque, Karine Caranhac, Gilbert Cohen‐Solal, Alain ESC Heart Fail Original Research Articles AIMS: This analysis aims to evaluate the budget impact of intravenous iron therapy with ferric carboxymaltose for patients with systolic chronic heart failure and iron deficiency, from the perspective of the French public health insurance. METHODS AND RESULTS: A budget impact model was adapted to forecast the budget impact over 5 years, according to two scenarios: one where patients receive ferric carboxymaltose according to market share forecast and another where patients are not treated for iron deficiency. Clinical data were extrapolated from pooled data from four randomized controlled trials. The time horizon was extended to 5 years by applying transition probabilities estimated from the CONFIRM‐HF trial. Epidemiological parameters for France were derived from the literature. Cost parameters were derived from national available databases. In the base case analysis, the modelled 5 year cost difference between the scenarios with ferric carboxymaltose vs. no iron deficiency treatment in a population of 189 334 prevalent and incident patients led to €0.8m savings. The cumulative savings resulted from a reduction in the hospitalization costs associated with worsening heart failure (€−35.8m) as well as a reduction in the follow‐up costs (€−2.9m). These cost savings outweighed the costs of ferric carboxymaltose treatment (€37.7m). Sensitivity analyses showed that the budget impact varied from €−34m to €+146m. Parameters with the most impact on the budget were the hospitalization rate for patients not treated for iron deficiency, the number of ambulatory sessions needed, the absence of hospitalization cost differentiation between New York Heart Association classes, and administration settings costs. CONCLUSIONS: Iron deficiency treatment with ferric carboxymaltose in systolic chronic heart failure patients results in an improvement of New York Heart Association class and thereby increases the well‐being of the patients, while providing an overall cost saving for the French national health insurance. John Wiley and Sons Inc. 2019-04-25 /pmc/articles/PMC6487717/ /pubmed/31021531 http://dx.doi.org/10.1002/ehf2.12432 Text en © 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Bourguignon, Sandrine
Faller, Mathilde
Champs, François‐Olivier
Moutier, Hélène
Levesque, Karine
Caranhac, Gilbert
Cohen‐Solal, Alain
Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
title Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
title_full Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
title_fullStr Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
title_full_unstemmed Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
title_short Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
title_sort budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in france
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487717/
https://www.ncbi.nlm.nih.gov/pubmed/31021531
http://dx.doi.org/10.1002/ehf2.12432
work_keys_str_mv AT bourguignonsandrine budgetimpactofintravenousferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyinfrance
AT fallermathilde budgetimpactofintravenousferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyinfrance
AT champsfrancoisolivier budgetimpactofintravenousferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyinfrance
AT moutierhelene budgetimpactofintravenousferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyinfrance
AT levesquekarine budgetimpactofintravenousferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyinfrance
AT caranhacgilbert budgetimpactofintravenousferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyinfrance
AT cohensolalalain budgetimpactofintravenousferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyinfrance